A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

Clinical trial NCT03706690 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03706690
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2018-11-27
Primary completion: 2024-06-23
Enrollment: 407

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.